Literature DB >> 1337634

Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India.

C P Thakur1, P Olliaro, S Gothoskar, S Bhowmick, B K Choudhury, S Prasad, M Kumar, B B Verma.   

Abstract

A 20 d drug regimen of aminosidine (= paromomycin) at 12 mg/kg/d in combination with sodium stibogluconate at 20 mg/kg/d proved efficacious and well-tolerated in patients with visceral leishmaniasis in the State of Bihar, India. Eighteen of 22 evaluable patients achieved an ultimate cure. The remaining 4 patients, although not cleared of parasites, had their parasite grade reduced and also improved clinically. This confirms prior findings in Kenyan patients with kala-azar, and indicates that this regimen is a valid alternative to antimonial compounds alone in the State of Bihar, where cases of kala-azar not responding to antimonial drugs and intolerant of pentamidine are increasingly recorded.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1337634     DOI: 10.1016/0035-9203(92)90150-b

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  18 in total

1.  Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.

Authors:  T K Jha; P Olliaro; C P Thakur; T P Kanyok; B L Singhania; I J Singh; N K Singh; S Akhoury; S Jha
Journal:  BMJ       Date:  1998-04-18

Review 2.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

3.  Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient.

Authors:  Patricia Barragán; Rogelio López-Velez; Montserrat Olmo; Daniel Podzamczer
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

Review 4.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

5.  Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects.

Authors:  T P Kanyok; A D Killian; K A Rodvold; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Visceral leishmaniasis in Malta--an 18 year paediatric, population based study.

Authors:  V Grech; J Mizzi; M Mangion; C Vella
Journal:  Arch Dis Child       Date:  2000-05       Impact factor: 3.791

7.  Miltefosine (Impavido): the first oral treatment against leishmaniasis.

Authors:  H Sindermann; S L Croft; K R Engel; W Bommer; H J Eibl; C Unger; J Engel
Journal:  Med Microbiol Immunol       Date:  2003-09-26       Impact factor: 3.402

8.  Liposomal amphotericin B and leishmaniasis: dose and response.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  J Glob Infect Dis       Date:  2010-05

Review 9.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

10.  Ribosomes of Leishmania are a target for the aminoglycosides.

Authors:  M Maarouf; F Lawrence; S L Croft; M Robert-Gero
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.